ACHV Achieve Life Sciences Inc.

1.53
+0.05  (+3%)
Previous Close 1.48
Open 1.47
Price To Book 1.08
Market Cap 12,391,197
Shares 8,097,763
Volume 58,813
Short Ratio
Av. Daily Volume 117,986
Stock charts supplied by TradingView

NewsSee all news

  1. Achieve Life Sciences Announces Completion of Maximum Tolerated Dose Study

    SEATTLE and VANCOUVER, British Columbia, Sept. 30, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of

  2. Achieve Life Sciences Announces Final Phase 2b ORCA-1 Trial Data Presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference

    SEATTLE and VANCOUVER, British Columbia, Sept. 13, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of

  3. Achieve Life Sciences to Host Investor Day on September 20th Including Roundtable Discussion with Smoking Cessation Medical Experts and Final Data from the Phase 2b ORCA-1 Trial

    SEATTLE and VANCOUVER, British Columbia, Sept. 5, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of

  4. Achieve Life Sciences Announces Presentations at Upcoming Investor Conferences

    SEATTLE and VANCOUVER, British Columbia, Sept. 4, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b data met primary endpoint in 3/4 arms - June 11, 2019.
Cytisine
Smoking cessation

Latest News

  1. Achieve Life Sciences Announces Completion of Maximum Tolerated Dose Study

    SEATTLE and VANCOUVER, British Columbia, Sept. 30, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of

  2. Achieve Life Sciences Announces Final Phase 2b ORCA-1 Trial Data Presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference

    SEATTLE and VANCOUVER, British Columbia, Sept. 13, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of

  3. Achieve Life Sciences to Host Investor Day on September 20th Including Roundtable Discussion with Smoking Cessation Medical Experts and Final Data from the Phase 2b ORCA-1 Trial

    SEATTLE and VANCOUVER, British Columbia, Sept. 5, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of

  4. Achieve Life Sciences Announces Presentations at Upcoming Investor Conferences

    SEATTLE and VANCOUVER, British Columbia, Sept. 4, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of